Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia

Objective: Atherogenic dyslipidemia is highly associated with coronary heart disease and is characterized by elevated triglycerides (TG), low high-density lipoprotein cholesterol (HDL-C), and elevated low-density lipoprotein cholesterol (LDL-C). The combination of statins and fibrates is a common modality to treat individuals with atherogenic dyslipidemia. We sought to identify single nucleotide polymorphisms (SNPs) associated with HDL-C, TG, and apolipoprotein A1 (ApoA-I) response to combination therapy with statins and fenofibric acid (FA) in individuals with atherogenic dyslipidemia. Methods: 2228 individuals with mixed dyslipidemia who were participating in a multicenter, randomized, double-blind, active-controlled study comparing FA alone, in combination with a statin, or statin alone for a 12-week period, were genotyped for 304 candidate SNPs. A multivariate linear regression analysis for percent change in HDL-C, ApoA-I and TG levels was performed. Results: SNPs in the apolipoprotein (APO) A5-ZNF259 region rs3741298 (P = 1.8 x 10(-7)), rs964184 (P=3.6 x 10(-6)), rs651821 (P=4.5 x 10(-5)), and rs10750097 (P=1 x 10(-4)), were significantly associated with HDL-C response to combination therapy with statins and FA, with a similar association identified for ApoA-I. A haplotype composed of the minor alleles of SNPs rs3741298, rs964184, and rs10750097, was associated with a positive response to statins and FA (P = 8.7 x 10(-7)) and had a frequency of 18% in the study population. Conclusion: In a population with atherogenic dyslipidemia, common SNPs and haplotypes within the AP0A5-ZNF259 region are highly associated with HDL-C and ApoA-I response to combination therapy with statins and FA. (C) 2011 Published by Elsevier Ireland Ltd.